IP Library Granted Patent US 8,487,129
Granted Patent B2
US 8,487,129 · App. 13/294,677 · Granted Jul 16, 2013

Heterodimers of glutamic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,487,129
App. No.
13/294,677
Granted
Jul 16, 2013
Kind
B2
Abstract

Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Z is H or C 1 -C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 6 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

Claims (111)

1. A compound of Formula (I)

wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 3 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′,

Q is C(O), O, NR′, S(O) 2 , C(O) 2 , or (CH 2 ) p ,

Y is C(O), O, NR′, S(O) 2 , C(O) 2 , or (CH 2 ) p ,

Z is H or C 1 -C 4 alkyl,

m is 0, 1, 2, 3, 4 or 5,

n is 0, 1, 2, 3, 4, 5 or 6,

p is 0, 1, 2, 3, 4, 5 or 6, and

R′ independently is H, a C 6 -C 12 substituted or unsubstituted aryl, a C 3 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl,

when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 3 -C 12 heteroaryl, —NR′R′ or COOZ,

further wherein

at least one of Q and Y comprises a heteroatom selected from the group consisting of O, S, and N; and

(i) at least one of R or R′ is a C 6 -C 12 aryl or C 3 -C 12 heteroaryl substituted with a halogen or

(ii) at least one of R or R′ is a C 3 -C 12 heteroaryl;

or a pharmaceutically acceptable salt of the compound of Formula (I).

2. The compound or salt of claim 1 , wherein the halogen is a radiohalogen.

3. The compound or salt of claim 1 , wherein

n is 0 or 1;

m is 0, 1, 2, 3 or 4;

Q is NR′;

Y is C(O) or CH 2 ; and

R is a C 6 -C 12 substituted or unsubstituted aryl.

4. The compound or salt of claim 3 , wherein R is a phenyl moiety substituted with a halogen.

5. The compound or salt of claim 1 , wherein the compound is:

wherein the hydrogen of the carboxy groups of any of the above compounds can be substituted with C 1 -C 4 alkyl, and

X is selected from the group consisting of halogen, radiohalogen, I-123, I-125, I-131, I-124, Br-75, Br-77, and F-18.

6. The compound or salt of claim 1 , wherein the compound is:

7. The compound or salt of claim 1 , wherein

n is 0 or 1;

m is 0, 1, 2, 3 or 4;

Q is NR′;

Y is C(O) or CH 2 ;

R is a —CH 2 (CH 2 ) 1-4 CHNR′R′; and

R′ independently is a C 1 -C 2 alkyl substituted with a pyridine or carboxy group.

8. A compound of formula III:

wherein

L is a bond, an optionally substituted C 1 -C 15 alkyl, C 1 -C 15 alkenyl, or C 1 -C 15 alkynyl, or —[(CH 2 ) q O] s —, wherein q and s are independently an integer of 1 to 10;

E is —NR′R′;

Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

Y is C(O), 0 , NR′, S, S(O) 2 , C(O) 2 , or (CH 2 ) p ;

Z is H or C 1 -C 4 alkyl;

m is 0, 1, 2, 3, 4 or 5;

n is 0, 1, 2, 3, 4, 5 or 6;

n′ is 0, 1, 2, 3, 4, 5 or 6;

p is 0, 1, 2, 3, 4, 5 or 6;

R′ independently is H, a C 6 -C 12 substituted or unsubstituted aryl, a C 3 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 14 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 3 -C 12 heteroaryl, —NR′R′ or COOZ;

or a pharmaceutically acceptable salt thereof.

9. The compound or salt of claim 8 , wherein the compound is

wherein the hydrogen of the carboxy groups of any of the above compounds can be substituted with C 1 -C 4 alkyl.

10. The compound or salt of claim 8 , wherein the compound is

wherein the hydrogen of the carboxy groups of any of the above compounds can be substituted with C 1 -C 4 alkyl.

11. A compound or salt of claim 8 , wherein the compound is:

wherein the hydrogen of the carboxy groups of the above compounds can be substituted with C 1 -C 4 alkyl.

12. The compound or salt of claim 1 , wherein the compound is of the Formula (II):

wherein R, Q, Y, Z, m and n are as defined in claim 1 .

13. A radionuclide chelate complex comprising the compound or salt of claim 1 and a radionuclide.

14. The radionuclide chelate complex of claim 13 , wherein the radionuclide is an imaging radionuclide.

15. The radionuclide chelate complex of claim 13 , wherein the radionuclide is a therapeutic radionuclide.

16. The radionuclide chelate complex of claim 13 , wherein the radionuclide chelate complex is a (technetium-99m)Tc(CO) 3 chelate complex or a (rhenium-186/188)Re(CO) 3 chelate complex.

17. A radionuclide chelate complex, wherein the radionuclide chelate complex is

wherein the hydrogen of the carboxy groups of any of the above compounds can be substituted with C 1 -C 4 alkyl.

18. The compound or salt of claim 1 , wherein the compound is of Formula Iib:

wherein —Y—R is selected from the group consisting of:

wherein X is selected from the group consisting of: I, Br, Cl, F, and H.

19. The compound or salt of claim 1 , wherein the compound is of the following structure:

wherein the hydrogen of the carboxy groups of the compound or salt can be substituted with C 1 -C 4 alkyl; and

X is selected from halogen and H.

20. The compound or salt of claim 1 , wherein the compound is of the following structure:

wherein the hydrogen of the carboxy groups of the compound or salt can be substituted with C 1 -C 4 alkyl; and

X is selected from halogen and H.

21. The compound or salt of claim 1 , selected from the group consisting of:

and

22. The compound or salt of claim 1 selected from the group consisting of:

23. The compound or salt of claim 1 , selected from the group consisting of:

24. The compound or salt of claim 18 , wherein X is a radiohalogen of I, Br, Cl or F.

25. The compound or salt of claim 24 , wherein the radiohalogen is an imaging radiohalogen.

26. The compound or salt of claim 24 , wherein the radiohalogen is a therapeutic radiohalogen.

27. The compound or salt of claim 24 , wherein the radiohalogen is I-123, I-125, I-131, I-124, Br-75, Br-77, or F-18.

28. A radionuclide chelate complex comprising the compound or salt of claim 8 and a radionuclide.

29. The compound or salt of claim 2 , wherein the radiohalogen is an imaging radiohalogen.

30. The compound or salt of claim 2 , wherein the radiohalogen is a therapeutic radiohalogen.

31. The compound or salt of claim 2 , wherein the radiohalogen is I-123, I-125, I-131, I-124, Br-75, Br-77, or F-18.

32. The compound or salt of claim 8 , wherein n′ is 0.

33. The compound or salt of claim 32 , wherein L is an optionally substituted C 1 -C 15 alkyl.

34. The compound or salt of claim 33 , wherein n is 0.

35. The compound or salt of claim 34 , wherein Q is NR′.

36. The compound or salt of claim 33 , wherein Q is NR′ and Y is C(O).

37. The compound or salt of claim 35 , wherein R′ independently is H, a C 3 -C 12 substituted or unsubstituted heteroaryl, or a C 1 -C 15 substituted or unsubstituted alkyl.

38. The compound or salt of claim 36 , wherein R′ independently is H, a C 3 -C 12 substituted or unsubstituted heteroaryl, or a C 1 -C 15 substituted or unsubstituted alkyl.

39. The compound or salt of claim 37 , wherein R′ independently is a C 3 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 15 substituted alkyl, and when substituted, the C 1 -C 15 substituted alkyl is substituted with COOH.

40. The compound or salt of claim 38 , wherein R′ independently is a C 3 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 15 substituted alkyl, and when substituted, the C 1 -C 15 substituted alkyl is substituted with COOH.

41. The compound or salt of claim 19 , wherein the halogen is a radiohalogen.

42. The compound or salt of claim 19 , wherein X is selected from the group consisting of: I, Br, Cl, F, I-123, I-125, I-131, I-124, Br-75, Br-77, and F-18, and H.

43. The compound or salt of claim 19 , wherein X is I-123, I-125, I-131, or I-124.

44. The compound or salt of claim 19 having the formula:

45. The compound or salt of claim 20 , wherein the halogen is a radiohalogen.

46. The compound or salt of claim 20 , wherein X is selected from the group consisting of: I, Br, Cl, F, I-123, I-125, I-131, I-124, Br-75, Br-77, and F-18, and H.

47. The compound or salt of claim 20 , wherein X is I-123, I-125, I-131, or I-124.

48. The compound or salt of claim 20 having the formula:

49. The compound or salt of claim 1 , wherein the compound is of the following structure:

wherein the hydrogen of the carboxy groups of the compound or salt can be substituted with C 1 -C 4 alkyl; and

X is selected from halogen and H.

50. The compound or salt of claim 49 , wherein the halogen is a radiohalogen.

51. The compound or salt of claim 49 , wherein X is selected from the group consisting of: I, Br, Cl, F, I-123, I-125, I-131, I-124, Br-75, Br-77, and F-18, and H.

52. The compound or salt of claim 49 , wherein X is I-123, I-125, I-131, or I-124.

53. The compound or salt of claim 49 having the formula:

54. A compound having the formula:

wherein X is selected from the group consisting of: I, Br, Cl, F, and H;

or a pharmaceutically acceptable salt thereof.

55. The compound or salt of claim 54 , wherein X is a radiohalogen of I, Br, Cl or F.

56. The compound or salt of claim 54 having the formula:

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC
Reel/Frame 062047/0915 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
SECURITY AGREEMENT Recorded Aug 19, 2020
From: PROGENICS PHARMACEUTICALS, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY LLC
To: WELLS FARGO BANK, N.A.
Reel/Frame 053538/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: BABICH, JOHN W.; ZIMMERMAN, CRAIG N.; MARESCA, KEVIN P.
To: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
Reel/Frame 027749/0749 →